Instrument to collect fogwater for chemical analysis

An instrument is presented which collects large samples of ambient fogwater by impaction of droplets on a screen. The collection efficiency of the instrument is determined as a function of droplet size, and it is shown that fog droplets in the range 3–100-µm diameter are efficiently collected. No significant evaporation or condensation occurs at any stage of the collection process. Field testing indicates that samples collected are representative of the ambient fogwater. The instrument may easily be automated, and is suitable for use in routine air quality monitoring programs

New separation protocol reveals spray painting as a neglected source of microplastics in soils

Microplastics are recently discovered contaminants, yet knowledge on their sources and analysis is limited. For instance, paint microplastics are poorly known because soil separation protocols using flotation solutions cannot separate paint microplastics due to the higher density of paint microplastic versus common microplastics. Here, we designed a new two-step density separation protocol for paint microplastics, allowing paint microplastics to be separated from the soil without digestion. Paint particles were separated from soil samples collected around the graffiti wall at the Mauerpark, Berlin, then quantified according to their shape and color characteristic. The presence of polymers as binders in the paint particles was verified by Fourier transform infrared spectroscopy. Results show concentrations from 1.1 × 105 to 2.9 × 105 microplastics per Kg of dry soil, representing the highest microplastic concentration ever reported in the literature. Particle concentrations decreased and the median size increased with soil depth. Our results provide first evidence that spray painting, a technique with a wide range of applications from industry to art, leaves a legacy of environmental microplastic in soils that has so far gone unnoticed

How Soil Invertebrates Deal With Microplastic Contamination

Small animals living in soils, called soil invertebrates, represent a very diverse group of soil inhabitants. They include earthworms, woodlice, spiders, springtails, mites, and some insects. Soil invertebrates feed on dead plants, on fungi and bacteria, or on other soil invertebrates. The many ways soil invertebrates interact with each other, and the large number of different species, make life in soils complex and difficult to understand. Unfortunately, soil invertebrates have been dealing with soil pollution, including contamination with tiny particles of plastic called microplastics for decades now. But are microplastics harmful to these organisms? Can microplastics be passed between soil invertebrates when one feeds on another? Most questions about microplastics and soil invertebrates have been investigated using earthworms, but a few studies on others, like springtails, mites, and nematodes, also exist. In this article, we summarize the effects of microplastics on soil invertebrates

Endovascular treatment of renal artery thrombosis caused by umbilical artery catheterization

AbstractRenal arterial thrombosis, usually in association with aortic thrombosis, has been reported as a result of prolonged neonatal umbilical artery catheterization. A case of renal artery thrombosis attributable to umbilical artery catheterization, resulting in malignant renovascular hypertension, in a 15-day-old neonate, treated by catheter-directed thrombolysis through the involuting umbilical artery, was studied. Resolution of systemic hypertension and partial return of right renal function followed rapid thrombus dissolution. (J Vasc Surg 1998;28:949-53.

Photodegradation modifies microplastic effects on soil properties and plant performance

1. Microplastics (MPs) in soil affect plant–soil systems depending on their shape and polymer type. However, previous research has not yet considered the effects of degraded plastics, which are the plastic materials actually present in the environment. 2. We selected eight MPs representing different shapes (fibres, films and foams) and polymer types, and exposed them to UV-C degradation. Each MP was mixed with soil at a concentration of 0.4% (w/w). The phytometer Daucus carota grew in each pot. At harvest, soil properties and plant biomass were measured. 3. Photodegradation altered MP physical and chemical properties, impacting plant–soil systems. MP degradation effects on plant and soil were observed with fibres and foams, but there were negligible effects with films. The latter could be explained by the polymer structure of films and manufacturer's additives, potentially delaying their degradation. 4. Degraded fibres increased soil respiration more than their non-degraded counterparts, as photodegradation increased the positive effects of fibres on soil water retention. The emergence of oxygenated groups during degradation may have increased the hydrophilicity of fibres, enhancing their ability to retain water. Degraded foams increased soil respiration, which could be related to the possible leaching of organic substances with lower partition coefficients, which may promote soil microbial activity. 5. In contrast, degraded foams decreased soil aggregation, likely as degradation produced larger holes increasing their permeability. Also, the increase in hydrophilic molecules could have decreased soil particle cohesiveness. Degraded fibres and foams increased shoot and root mass as a result of MP effects on soil properties. Photodegraded MPs affected root traits, which could be linked to MP effects on soil water status and plant coping strategies. 6. Synthesis and applications. Photodegradation can intensify the effects that microplastics (MPs) have on plant–soil systems, which would have frequently been underestimated had we only worked with pristine MPs. Plastic companies, agricultural practitioners and researchers should consider that plastics are being degraded as they enter the soil. Policies should promote practices to minimize MP accumulation in soils and ensure their proper disposal

Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.

One major hurdle to the success of adoptive T-cell therapy is the identification of antigens that permit effective targeting of tumors in the absence of toxicities to essential organs. Previous work has demonstrated that T cells engineered to express chimeric antigen receptors (CAR-T cells) targeting the murine homolog of the colorectal cancer antigen GUCY2C treat established colorectal cancer metastases, without toxicity to the normal GUCY2C-expressing intestinal epithelium, reflecting structural compartmentalization of endogenous GUCY2C to apical membranes comprising the intestinal lumen. Here, we examined the utility of a human-specific, GUCY2C-directed single-chain variable fragment as the basis for a CAR construct targeting human GUCY2C-expressing metastases. Human GUCY2C-targeted murine CAR-T cells promoted antigen-dependent T-cell activation quantified by activation marker upregulation, cytokine production, and killing of GUCY2C-expressing, but not GUCY2C-deficient, cancer cells in vitro. GUCY2C CAR-T cells provided long-term protection against lung metastases of murine colorectal cancer cells engineered to express human GUCY2C in a syngeneic mouse model. GUCY2C murine CAR-T cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C, providing durable survival in a human xenograft model in immunodeficient mice. Thus, we have identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the treatment of GUCY2C-expressing metastatic colorectal cancer

Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.

Background: The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8+, but not CD4+, T-cell responses that deliver anti-tumor immunity without autoimmunity in mice. Here, the cancer vaccine Ad5-GUCY2C-PADRE was evaluated in a first-in-man phase I clinical study of patients with early-stage colorectal cancer to assess its safety and immunological efficacy. Methods: Ten patients with surgically-resected stage I or stage II (pN0) colon cancer received a single intramuscular injection of 1011 viral particles (vp) of Ad5-GUCY2C-PADRE. Safety assessment and immunomonitoring were carried out for 6 months following immunization. This trial employed continual monitoring of both efficacy and toxicity of subjects as joint primary outcomes. Results: All patients receiving Ad5-GUCY2C-PADRE completed the study and none developed adverse events greater than grade 1. Antibody responses to GUCY2C were detected in 10% of patients, while 40% exhibited GUCY2C-specific T-cell responses. GUCY2C-specific responses were exclusively CD8+ cytotoxic T cells, mimicking pre-clinical studies in mice in which GUCY2C-specific CD4+ T cells are eliminated by self-tolerance, while CD8+ T cells escape tolerance and mediate antitumor immunity. Moreover, pre-existing neutralizing antibodies (NAbs) to the Ad5 vector were associated with poor vaccine-induced responses, suggesting that Ad5 NAbs oppose GUCY2C immune responses to the vaccine in patients and supported by mouse studies. Conclusions: Split tolerance to GUCY2C in cancer patients can be exploited to safely generate antigen-specific cytotoxic CD8+, but not autoimmune CD4+, T cells by Ad5-GUCY2C-PADRE in the absence of pre-existing NAbs to the viral vector. TRIAL REGISTRATION: This trial (NCT01972737) was registered at ClinicalTrials.gov on October 30th, 2013. https://clinicaltrials.gov/ct2/show/NCT01972737

Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.

Abstract OBJECTIVE: To study rituximab in pediatric neuromyelitis optica (NMO)/NMO spectrum disorders (NMOSD) and the relationship between rituximab, B cell repopulation, and relapses in order to improve rituximab monitoring and redosing. METHODS: Multicenter retrospective study of 16 children with NMO/NMOSD receiving 652 rituximab courses. According to CD19 counts, events during rituximab were categorized as "repopulation," "depletion," or "depletion failure" relapses (repopulation threshold CD19 6510 7 10(6) cells/L). RESULTS: The 16 patients (14 girls; mean age 9.6 years, range 1.8-15.3) had a mean of 6.1 events (range 1-11) during a mean follow-up of 6.1 years (range 1.6-13.6) and received a total of 76 rituximab courses (mean 4.7, range 2-9) in 42.6-year cohort treatment. Before rituximab, 62.5% had received azathioprine, mycophenolate mofetil, or cyclophosphamide. Mean time from rituximab to last documented B cell depletion and first repopulation was 4.5 and 6.8 months, respectively, with large interpatient variability. Earliest repopulations occurred with the lowest doses. Significant reduction between pre- and post-rituximab annualized relapse rate (ARR) was observed (p = 0.003). During rituximab, 6 patients were relapse-free, although 21 relapses occurred in 10 patients, including 13 "repopulation," 3 "depletion," and 4 "depletion failure" relapses. Of the 13 "repopulation" relapses, 4 had CD19 10-50 7 10(6) cells/L, 10 had inadequate monitoring ( 641 CD19 in the 4 months before relapses), and 5 had delayed redosing after repopulation detection. CONCLUSION: Rituximab is effective in relapse prevention, but B cell repopulation creates a risk of relapse. Redosing before B cell repopulation could reduce the relapse risk further. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that rituximab significantly reduces ARR in pediatric NMO/NMOSD. This study also demonstrates a relationship between B cell repopulation and relapses